Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy: review
Introduction - Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is a relatively new disease entity caused by ICI agents during cancer therapy. Reactive arthritis (ReA) is a well-known disease entity caused by urogenital or gastrointestinal bacterial infection or pneumonia. In this...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
April 2022
|
| In: |
Biomedicine & pharmacotherapy
Year: 2022, Volume: 148, Pages: 1-9 |
| ISSN: | 1950-6007 |
| DOI: | 10.1016/j.biopha.2022.112687 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.biopha.2022.112687 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0753332222000750 
|
| Author Notes: | Anders Kirkegaard Jensen, Katerina Chatzidionysiou, Christopher Kirkegaard Torp, Anne Sofie Sørensen, Helene Broch Tenstad, Valentin S. Schäfer, Marie Kostine, Søren Jacobsen, Jan Leipe, Tue Wenzel Kragstrup |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1883720516 | ||
| 003 | DE-627 | ||
| 005 | 20240703154402.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240318s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2022.112687 |2 doi | |
| 035 | |a (DE-627)1883720516 | ||
| 035 | |a (DE-599)KXP1883720516 | ||
| 035 | |a (OCoLC)1443645762 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Jensen, Anders Kirkegaard |e VerfasserIn |0 (DE-588)1323767282 |0 (DE-627)1883721350 |4 aut | |
| 245 | 1 | 0 | |a Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy |b review |c Anders Kirkegaard Jensen, Katerina Chatzidionysiou, Christopher Kirkegaard Torp, Anne Sofie Sørensen, Helene Broch Tenstad, Valentin S. Schäfer, Marie Kostine, Søren Jacobsen, Jan Leipe, Tue Wenzel Kragstrup |
| 264 | 1 | |c April 2022 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 25. Februar 2022, Artikelversion: 25. Februar 2022 | ||
| 500 | |a Gesehen am 18.03.2024 | ||
| 520 | |a Introduction - Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is a relatively new disease entity caused by ICI agents during cancer therapy. Reactive arthritis (ReA) is a well-known disease entity caused by urogenital or gastrointestinal bacterial infection or pneumonia. In this sense, ICI-IA and ReA are both defined by a reaction to a well-specified causal event. As a result, comparing these diseases may help to determine therapeutic strategies. - Methods - We compared ICI-IA and ReA with special focus on pharmacological management. Specifically regarding treatment, we conducted a literature search of studies published in the PubMed database. Inclusion criteria were studies on treatment with non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids (GC), or disease modifying antirheumatic drugs (DMARDs) in ICI-IA or ReA. During systematic selection, 21 studies evaluating ICI-IA and 14 studies evaluating ReA were included. - Results - In ICI-IA, prospective and retrospective studies have shown effects of non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoid (GC), sulfasalazine (SSZ), methotrexate (MTX), hydroxychloroquine (HCQ) and TNFi. In ReA, retrospective studies evaluated NSAIDs and GC. A randomized controlled trial reported the effect of SSZ, and a retrospective study reported the effect of MTX and SSZ in combination with tumor necrosis factor alpha inhibition (TNFi). For both entities, small case reports show treatment effects of interleukin 6 receptor inhibition (IL-6Ri). - Discussion - This literature review identified both similarities and differences regarding the pathogenesis and clinical features of ReA and ICI-IA. Studies on treatment reported effectiveness of NSAIDs, GC, MTX, SSZ and TNFi in both diseases. Further, small case reports showed effects of IL-6Ri. | ||
| 650 | 4 | |a Autoimmunity | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Immune checkpoint inhibitor | |
| 650 | 4 | |a Immune checkpoint inhibitor induced inflammatory arthritis | |
| 650 | 4 | |a Immune related adverse events | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Reactive arthritis | |
| 700 | 1 | |a Chatzidionysiou, Katerina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Torp, Christopher Kirkegaard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sørensen, Anne Sofie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tenstad, Helene Broch |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schäfer, Valentin S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kostine, Marie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jacobsen, Søren |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leipe, Jan |d 1976- |e VerfasserIn |0 (DE-588)131797824 |0 (DE-627)51426280X |0 (DE-576)298758563 |4 aut | |
| 700 | 1 | |a Kragstrup, Tue Wenzel |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy |d Amsterdam [u.a.] : Elsevier Science, 1989 |g 148(2022) vom: Apr., Artikel-ID 112687, Seite 1-9 |h Online-Ressource |w (DE-627)306717565 |w (DE-600)1501510-5 |w (DE-576)261593021 |x 1950-6007 |7 nnas |a Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy review |
| 773 | 1 | 8 | |g volume:148 |g year:2022 |g month:04 |g elocationid:112687 |g pages:1-9 |g extent:9 |a Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy review |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.biopha.2022.112687 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0753332222000750 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240318 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 131797824 |a Leipe, Jan |m 131797824:Leipe, Jan |d 60000 |d 61400 |e 60000PL131797824 |e 61400PL131797824 |k 0/60000/ |k 1/60000/61400/ |p 9 | ||
| 999 | |a KXP-PPN1883720516 |e 4501473304 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Online verfügbar: 25. Februar 2022, Artikelversion: 25. Februar 2022","Gesehen am 18.03.2024"],"physDesc":[{"extent":"9 S."}],"name":{"displayForm":["Anders Kirkegaard Jensen, Katerina Chatzidionysiou, Christopher Kirkegaard Torp, Anne Sofie Sørensen, Helene Broch Tenstad, Valentin S. Schäfer, Marie Kostine, Søren Jacobsen, Jan Leipe, Tue Wenzel Kragstrup"]},"person":[{"given":"Anders Kirkegaard","family":"Jensen","display":"Jensen, Anders Kirkegaard","role":"aut","roleDisplay":"VerfasserIn"},{"given":"Katerina","family":"Chatzidionysiou","roleDisplay":"VerfasserIn","role":"aut","display":"Chatzidionysiou, Katerina"},{"display":"Torp, Christopher Kirkegaard","role":"aut","roleDisplay":"VerfasserIn","family":"Torp","given":"Christopher Kirkegaard"},{"display":"Sørensen, Anne Sofie","role":"aut","roleDisplay":"VerfasserIn","given":"Anne Sofie","family":"Sørensen"},{"roleDisplay":"VerfasserIn","display":"Tenstad, Helene Broch","role":"aut","given":"Helene Broch","family":"Tenstad"},{"given":"Valentin S.","family":"Schäfer","roleDisplay":"VerfasserIn","display":"Schäfer, Valentin S.","role":"aut"},{"role":"aut","display":"Kostine, Marie","roleDisplay":"VerfasserIn","given":"Marie","family":"Kostine"},{"roleDisplay":"VerfasserIn","display":"Jacobsen, Søren","role":"aut","family":"Jacobsen","given":"Søren"},{"display":"Leipe, Jan","role":"aut","roleDisplay":"VerfasserIn","family":"Leipe","given":"Jan"},{"given":"Tue Wenzel","family":"Kragstrup","roleDisplay":"VerfasserIn","display":"Kragstrup, Tue Wenzel","role":"aut"}],"recId":"1883720516","id":{"doi":["10.1016/j.biopha.2022.112687"],"eki":["1883720516"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"disp":"Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy reviewBiomedicine & pharmacotherapy","part":{"year":"2022","extent":"9","volume":"148","pages":"1-9","text":"148(2022) vom: Apr., Artikel-ID 112687, Seite 1-9"},"origin":[{"dateIssuedDisp":"1989-","dateIssuedKey":"1989","publisherPlace":"Amsterdam [u.a.]","publisher":"Elsevier Science"}],"titleAlt":[{"title":"Biomedicine and pharmacotherapy"}],"title":[{"title_sort":"Biomedicine & pharmacotherapy","title":"Biomedicine & pharmacotherapy"}],"note":["Gesehen am 09.11.2020"],"pubHistory":["Nachgewiesen 43.1989 -"],"physDesc":[{"extent":"Online-Ressource"}],"recId":"306717565","id":{"eki":["306717565"],"issn":["1950-6007"],"zdb":["1501510-5"]}}],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"April 2022"}],"title":[{"title":"Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy","title_sort":"Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy","subtitle":"review"}],"language":["eng"]} | ||
| SRT | |a JENSENANDECOMPARISON2022 | ||